Mural Oncology plc MURA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
30/100
Developing

Ranked against 712 peers in Biotechnology

Key risks

  • ROIC Below WACC or Peers ROIC at 0th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where MURA ranks in Biotechnology

Mural Oncology plc ranks #517 of 713 scored companies in Biotechnology by moat score — the top 73%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
513 Cel-Sci Corporation CVM 30/100 Developing
514 SELLAS Life Sciences Group, Inc SLS 30/100 Developing
515 Genprex, Inc. GNPX 30/100 Developing
516 Intensity Therapeutics, Inc. INTS 30/100 Developing
517 Mural Oncology plc MURA 30/100 Developing
518 Annovis Bio, Inc. ANVS 30/100 Developing
519 Enveric Biosciences, Inc. ENVB 30/100 Developing
520 Longeveron Inc. LGVN 30/100 Developing
521 Immuneering Corporation IMRX 29/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How MURA scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 20 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 60 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding MURA's moat

What is Mural Oncology plc's moat score?

Mural Oncology plc (MURA) scores 30 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #517 of 713 scored companies in Biotechnology, the top 73%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (60/100) and its weakest is Capital Efficiency (20/100).

How does Mural Oncology plc compare with other Biotechnology companies?

Mural Oncology plc ranks #517 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Intensity Therapeutics, Inc. (INTS) at 30 just above it and Annovis Bio, Inc. (ANVS) at 30 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Mural Oncology plc scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Mural Oncology plc?

The Corporate Default template measures 6 defenses, and MURA scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (20), Resilience (60), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000